Popular Stories
- Arcutis Biotherapeutics (N
- Nexgel: Bringing Innovatio
- Ekso Bionics: Advancing Ra
- Esperion: Revolutionizing
- AMSC: Restructuring the Po
- Harrow Inc: Envisioning a
SAMPLE REPORTS
- Company Summary.pdf
- Daily Market Updates.pdf
- Initiating Coverage.pdf
- Investors' Presentation.pdf
- Portfolio Performance Analysis.pdf
- Pre-Result Analysis.pdf
- Result Review.pdf
- Short Initiating Coverage.pdf

AstraZeneca Covid Vaccine Tag

  • All
  • Beauty
  • Biotechnology
  • Cannabis
  • Communications
  • Education
  • Energy
  • Entertainment
  • Environment
  • ETFs
  • Finance
  • Fitness
  • Food and Beverage
  • Healthcare
  • Hospitality
  • Insider Trading
  • Investing Ideas
  • Macro
  • Market Insight
  • Miscellaneous
  • Power
  • Real Estate
  • Retail
  • Sectors
  • Security
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Should BeyondSpring be a part of your Portfolio?
Should BeyondSpring be a part of your Portfolio?

BeyondSpring, Inc. (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on creating transformative treatments for immune-oncology conditions. The Company’s lead candidate is plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), which possess a unique mechanism of action and was evaluated in Phase 3 clinical trials in...

27 October, 2021 0 Comments
Is it the end of the road for Ardelyx Inc?
Is it the end of the road for Ardelyx Inc?

Ardelyx, Inc. (NASDAQ: ARDX) lead candidate Tenapanor, is a targeted, first-in-class, oral, small molecule intended for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. The drug has the potential to become a foundational therapy for hyperphosphatemia and enable...

08 October, 2021 0 Comments
WordPress Video Lightbox Plugin